A federal appeals court has affirmed an earlier ruling by the Patient Trial and Appeal Board of the U.S. Patent and Trademark Office, invalidating 22 claims of a patent owned by United Therapeutics (NSDQ:UTHR).
The patent covered treprostinil, the active ingredient in both SteadyMed‘s (NSDQ:STDY) Trevyent and United Therapeutics’ Remodulin. The court’s ruling sent STDY shares up 8% today, trading at $3.40 apiece in mid-morning activity.
Get the full story at our sister site, Drug Delivery Business News.
The post Appeals court affirms ruling in United Therapeutics, SteadyMed patent spat appeared first on MassDevice.
from MassDevice http://ift.tt/2zYtQQ0
Cap comentari:
Publica un comentari a l'entrada